Regeneron Reports Phase 3 LIBERTY AD CAFÉ Results for Dupixent in Atopic Dermatitis

Regeneron and Sanofi today announced results from the Phase 3 LIBERTY AD CAFÉ trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis who had an inadequate response to cyclosporine or for whom cyclosporine was not medically advisable. The trial met its primary endpoint, demonstrating a significantly higher rate of clear or almost clear skin compared to placebo at week 16.